Last updated: April 23, 2026
Who Supplies Fluticasone Furoate for Pharmaceutical Use?
Fluticasone furoate is a synthetic, inhaled corticosteroid API used in multiple marketed respiratory products. Supply is typically split across (1) API manufacturers (active substance) and (2) companies supplying finished-dose inhalers or contract manufacturing for those combination products. The market also has material routed through distributors and global trading houses rather than direct manufacturer-to-customer shipments.
Which companies manufacture fluticasone furoate API?
In practice, fluticasone furoate API supply is dominated by established chemical and pharmaceutical intermediate producers with demonstrated capability to run high-value corticosteroid chemistry, including precise control of polymorph/impurity profiles and inhalation-grade specs.
Below are the company types and the most common “supplier” categories encountered in procurement:
API manufacturers (direct)
- Chemical/pharmaceutical API producers with capability for corticosteroid APIs and inhalation-grade batch release.
- Companies that sell fluticasone furoate API as a stand-alone drug substance to inhalation manufacturers and formulation CDMOs.
API traders and distributors
- Global distributors that buy API from one or more source manufacturers and resell under their own commercial documentation.
- Procurement channel for smaller inhalation formulators and contract manufacturers who do not qualify multiple direct API sources.
Finished-dose inhaler manufacturers (indirect supply)
- Market-facing companies that source API (including fluticasone furoate) and assemble combination devices and products (often with additional APIs such as vilanterol or umeclidinium, depending on indication and product line).
What are the typical procurement paths for fluticasone furoate?
Fluticasone furoate is usually acquired through one of these commercial paths:
- Direct API supply from an API manufacturer to the inhalation formulation company.
- Supply through a sourcing partner (distributor or trading company) that provides COA documentation and manages lead times.
- Integration through a CDMO/CMO where the formulation and packaging provider also sources API or qualifies an approved API vendor list.
Which finished products drive fluticasone furoate supply?
Fluticasone furoate is most visible through inhaled respiratory brands, where supply chain behavior follows device and formulation qualification cycles.
Common market contexts include:
- Inhaled corticosteroid (ICS) formulations where fluticasone furoate is the corticosteroid component.
- ICS/LABA combinations where fluticasone furoate is paired with a long-acting beta-agonist (device and delivery system are tightly linked to formulation and regulatory dossier decisions).
This matters because supplier continuity is often enforced by regulatory and quality documentation anchored to specific API grades and impurity controls.
Supplier qualification and documentation expectations (pharma-grade API)
Procurement and regulatory compliance typically require, at minimum:
- Drug Substance specification (assay, impurities, residual solvents where applicable, particle size if relevant to downstream process)
- Polymorph and solid-state control where the substance’s physical form impacts performance
- GMP manufacturing documentation and batch traceability
- Stability data supporting shelf life under defined storage conditions
- CoA with impurity breakdown and limits aligned to dossier
These requirements apply whether the “supplier” is an API manufacturer, distributor, or formulation CDMO.
Key Takeaways
- Fluticasone furoate supply is usually handled through qualified API manufacturers, distributors/traders, or finished-dose inhalation manufacturers/CDMOs that embed API sourcing into device and formulation qualification.
- Procurement decisions typically hinge on GMP status, solid-state and impurity control, and documented consistency of the specific API grade used in the regulated product.
- Inhaler-driven qualification cycles can create “sticky” supply relationships that prioritize continuity and dossier-aligned quality.
FAQs
1) Is fluticasone furoate typically sold as API or inside finished inhalers?
It is sold both ways: as API to formulation manufacturers and as part of finished inhalers where the inhaler company sources the API internally or through a CDMO supply chain.
2) Are API suppliers the same across different inhaler brands?
Not always. Different products can use different fluticasone furoate grades/specs, and supply is tied to regulatory documentation and quality agreements.
3) Why do distributors matter for fluticasone furoate procurement?
Distributors can provide commercial availability, lead-time management, and consolidated paperwork, but customers still need to verify underlying manufacturing origin and GMP documentation.
4) What quality controls are most important for fluticasone furoate supply?
Assay and impurity profile, residual solvents (where applicable), and solid-state form control, plus stability and batch traceability aligned with the regulatory dossier.
5) What determines whether an API supplier qualifies for an inhalation program?
Demonstrated GMP capability, ability to meet specific impurity and physical-form requirements, and successful integration into the customer’s regulatory and quality system.
References
[1] FDA. (n.d.). Drugs@FDA: Product information for fluticasone-containing inhalation products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. (n.d.). European Public Assessment Reports (EPAR) for fluticasone furoate-containing products. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] PubChem. (n.d.). Fluticasone furoate (CID) substance information. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/
